G

Guobang Pharma Ltd
SSE:605507

Watchlist Manager
Guobang Pharma Ltd
SSE:605507
Watchlist
Price: 21.27 CNY -3.23% Market Closed
Market Cap: 11.8B CNY
Have any thoughts about
Guobang Pharma Ltd?
Write Note

Guobang Pharma Ltd
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Guobang Pharma Ltd
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
G
Guobang Pharma Ltd
SSE:605507
Other Operating Expenses
ÂĄ5.8m
CAGR 3-Years
N/A
CAGR 5-Years
60%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Operating Expenses
-ÂĄ64.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Operating Expenses
ÂĄ32.1m
CAGR 3-Years
40%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Operating Expenses
ÂĄ438.9m
CAGR 3-Years
24%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Operating Expenses
ÂĄ8.3m
CAGR 3-Years
-46%
CAGR 5-Years
N/A
CAGR 10-Years
-34%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Operating Expenses
ÂĄ49.1m
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Guobang Pharma Ltd
Glance View

Market Cap
11.8B CNY
Industry
Pharmaceuticals

Guobang Pharma Ltd. engages in the research, development, manufacturing and sale of pharmaceutical products. The company is headquartered in Shaoxing, Zhejiang and currently employs 3,326 full-time employees. The company went IPO on 2021-08-02. The firm's pharmaceutical business includes raw materials, key pharmaceutical intermediates and preparations, and its main products include azithromycin, clarithromycin, and roxithromycin cephalosporin series products. The animal health products business includes animal protection raw materials, animal protection additives and preparations. The main products of veterinary antibiotics include florfenicol, enrofloxacin series, etc., and insecticides include diclazuril and cypronamine, and reparation products include premixes, powders, granules, etc.

Intrinsic Value
34.07 CNY
Undervaluation 38%
Intrinsic Value
Price
G

See Also

What is Guobang Pharma Ltd's Other Operating Expenses?
Other Operating Expenses
5.8m CNY

Based on the financial report for Dec 31, 2023, Guobang Pharma Ltd's Other Operating Expenses amounts to 5.8m CNY.

What is Guobang Pharma Ltd's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
60%

Over the last year, the Other Operating Expenses growth was -37%.

Back to Top